Skip to main content

MiNK Therapeutics, Inc.

INKT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001840229

No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by MiNK Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for MiNK Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for MiNK Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Wiinberg UlfDirector23,929Sep 2, 20264
Holcomb John BradleyDirector4,691Sep 2, 20264
Behner PeterDirector24,404Sep 2, 20264
Ryan BarbaraDirector23,591Sep 2, 20267
Corvese BrianDirector54,770Sep 2, 20264
Buell JenniferChief Executive Officer57,942Jan 14, 20262
Kadlec Robert PeterDirector19,126Dec 3, 20251
van Dijk Marcus AntoniusChief Scientific Officer27,363Jan 18, 20240
Agenus Inc10% Owner21,772,863Oct 16, 20230
Baldoni JohnDirector41,193Sep 6, 20230
Armen Garo HDirector1,866,400May 26, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 5, 2026 (view filing)Jun 41 dayRyan BarbaraDirectorSSale−1.50K$12.76−$19.1K−6.4%22.0K after2 lots
Mar 11, 2026 (view filing)Mar 9-102 daysRyan BarbaraDirectorSSale−1.50K$14.70−$22.1K−6.8%20.4K after4 lots
Mar 4, 2026 (view filing)Feb 27-Mar 25 daysLateRyan BarbaraDirectorSSale−500$10.85−$5.43K−2.2%21.9K after2 lots
Oct 16, 2023 (view filing)Oct 12-164 daysAgenus Inc10% OwnerPPurchase+23.0K$1.10+$25.3K+0.1%21.8M after3 lots
Oct 6, 2023 (view filing)Oct 42 daysAgenus Inc10% OwnerPPurchase+15.0K$1.09+$16.4K+0.1%21.7M after
Aug 31, 2023 (view filing)Aug 292 daysAgenus Inc10% OwnerPPurchase+29.7K$1.52+$45.1K+0.1%21.7M after
Aug 28, 2023 (view filing)Aug 24-284 daysAgenus Inc10% OwnerPPurchase+183.1K$1.53+$280.7K+0.9%21.7M after2 lots
May 12, 2023 (view filing)May 10-112 daysAgenus Inc10% OwnerPPurchase+45.4K$1.47+$66.7K+0.2%21.6M after2 lots
May 5, 2023 (view filing)May 5Same dayArmen Garo HDirectorSSale−100.0K$0.95−$95.0K−5.1%1.87M afterFrom original
May 5, 2023 (view filing)May 3-52 daysAgenus Inc10% OwnerPPurchase+250.4K$1.04+$260.4K+1.2%21.6M afterFrom original4 lots
May 4, 2023 (view filing)May 22 daysArmen Garo HDirectorPPurchase+100.0K$0.95+$95.0K+5.3%1.98M after
Jul 21, 2022 (view filing)Jul 18-193 daysLateWiinberg UlfDirectorPPurchase+20.0K$1.38+$27.6K+7.2%298.3K after2 lots
Oct 20, 2021 (view filing)Oct 191 dayAgenus Inc10% OwnerPPurchase+1.40M$12.00+$16.8M+7.2%20.9M after